Moteur de recherche d’entreprises européennes
Financement de l’UE (3 340 720 €) : Système d’aide à la décision et de gestion de l’information pour le cancer du sein Hor01/02/2016 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Système d’aide à la décision et de gestion de l’information pour le cancer du sein
Breast cancer is the most common type of cancer affecting woman in the EU. Multidisciplinary Breast Units (BUs) were introduced in order to deal efficiently with breast cancer cases, setting guideline-based quality procedures and a high standard of care. However, daily practice in the BUs is hampered by the complexity of the disease, the vast amount of patient and disease data available in the digital era, the difficulty in coordination, the pressure exerted by the system and the difficulty in deciding on cases that guidelines do not reflect. DESIREE aims to alleviate this situation by providing a web-based software ecosystem for the personalized, collaborative and multidisciplinary management of primary breast cancer (PBC) by specialized BUs. Decision support will be provided on the available therapy options by incorporating experience from previous cases and outcomes into an evolving knowledge model, going beyond the limitations of the few existing guideline-based decision support systems (DSS). Patient cases will be represented by a novel digital breast cancer patient (DBCP) data model, incorporating variables relevant for decision and novel sources of information and biomarkers of diagnostic and prognostic value, providing a holistic view of the patient presented to the BU through specialized visual exploratory interfaces. The influence of new variables and biomarkers in current and previous cases will be explored by a set of data mining and visual analytics tools, leveraging large amounts of retrospective data. Iintuitive web-based tools for multi-modality image analysis and fusion will be developed, providing advanced imaging biomarkers for breast and tumor characterization. Finally, a predictive tool for breast conservative therapy will be incorporated, based on a multi-scale physiological model, allowing to predict the aesthetic outcome of the intervention and the healing process, with important clinical and psychological implications for the patients.
| Arivis AG | 350 250 € |
| Assistance Publique Hopitaux de Paris | 194 375 € |
| Bilbomatica SA | 252 825 € |
| Ecg Médica SL | 168 975 € |
| Fundacion Centro de Tecnologias de Interaccion Visual y Comunicaciones Vicomtech | 586 624 € |
| Fundacion Onkologikoa Fundazioa | 155 115 € |
| Institut National de la Sante et de la Recherche Medicale | 402 035 € |
| Medical Innovation AND Technology Single Member PC | 261 466 € |
| Sistemas Genomicos SL | 99 125 € |
| THE Methodist Hospital Research Institute | 356 305 € |
| University OF Houston System | 0,00 € |
| University of Ulster | 513 625 € |
https://cordis.europa.eu/project/id/690238
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.